Literature DB >> 1716672

Development of subrenal capsule tumours following transplantation of rat RN6 multicell spheroids.

S Krajewski1, W Wechsler.   

Abstract

We describe here the growth rate, morphology and ultrastructure of the RN6 neurinoma spheroids in culture and after syngeneic transplantation under the renal capsule of adult BDIX rats, where sequential growth and tumour angiogenesis studies were performed. The tumour cells in solid avascular multicell spheroids (MTS) and in subrenal capsule tumours (SCT) showed similar morphology and ultrastructure. The vascularization of spheroids started 2 to 3 days after implantation under the renal capsule from proliferating venule-like vessels of the kidney parenchyma. The MTS were soon densely penetrated by hairpin loops of newly formed capillaries. Such vascularized spheroids grew rapidly. The morphology, ultrastructure and permeability characteristics of newly formed tumour vessels and their relationship to the development of tumour necrosis are described. This syngeneic model of subrenal capsule transplantation of neurogenic tumour spheroids appears to be useful for studies of the mechanisms of tumour angiogenesis, tumour necroses and the host response to malignant tumours of the nervous system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716672     DOI: 10.1007/bf00177534

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  50 in total

1.  [Immunomorphological studies of the central nervous system in chronic serum sickness in rabbits. Preliminary report].

Authors:  S Krajewski
Journal:  Neuropatol Pol       Date:  1979 Apr-Jun

2.  Immunohistochemical demonstration of serum proteins in human cerebral gliomas.

Authors:  R J Seitz; W Wechsler
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

3.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

4.  14-3-2 protein in rat primary and transplanted gliomas and neurinomas and in clonal cell lines.

Authors:  M Braun; A Grasso; W Wechsler
Journal:  Exp Brain Res       Date:  1976-05-10       Impact factor: 1.972

5.  Importance of size, sulfation, and anticoagulant activity in the potentiation of acidic fibroblast growth factor by heparin.

Authors:  J Sudhalter; J Folkman; C M Svahn; K Bergendal; P A D'Amore
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157

6.  Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo.

Authors:  N Bloksma; C F Kuper; F M Hofhuis; B Benaissa-Trouw; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Peripheral nerve sheath tumors: an electron microscopic study of 43 cases.

Authors:  R A Erlandson; J M Woodruff
Journal:  Cancer       Date:  1982-01-15       Impact factor: 6.860

8.  Cell degeneration and necrosis in experimental gliomas.

Authors:  P L Lantos; G J Pilkington
Journal:  Br J Exp Pathol       Date:  1978-02

9.  Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor.

Authors:  G Camussi; F Bussolino; G Salvidio; C Baglioni
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  1 in total

1.  Optimizing autologous bone contribution to implant osseointegration.

Authors:  Benjamin R Coyac; Qiang Sun; Brian Leahy; Giuseppe Salvi; Xue Yuan; John B Brunski; Jill A Helms
Journal:  J Periodontol       Date:  2020-05-28       Impact factor: 6.993

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.